19 Jan 2017 07:15
Hardman Research: Infacort® - On track to market
Infacort® - On track to market: Diurnal is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. It has two lead candidates - Infacort that completed its Phase III in Dec 2016 and Chronocort, currently in Phase III trials - targeted at rare diseases with unmet medical need, and is aiming to build a long-term 'Adrenal Franchise'. The completed Phase III trial confirmed that Infacort is well tolerated, achieved its primary endpoint and received the support of the parents and carers. Infacort will represent the first licenced cortisol replacement therapy for children and is on track to achieve market authorisation in late 2017 and sales in early 2018.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/19.01.17-infacort-on-track-to-market.pdf
To contact us: Hardman & Co 11/12 Tokenhouse Yard London EC2R 7AS | Contact: Dr Martin Hall mh@hardmanandco.com Dr Dorothea Hill dmh@hardmanandco.com Dr Gregoire Pave gp@hardmanandco.com Telephone: +44 20 7929 3399 Follow us on Twitter @HardmanandCo
|
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.